Haemonetics (HAE) has disclosed a new risk, in the Environmental / Social category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haemonetics faces heightened business risks due to climate change and the associated regulatory measures. The unpredictability of long-term climate effects threatens their operational efficiency and supply chain, particularly in the sourcing of raw materials and essential natural resources like water. Moreover, stringent climate-related legislation could impose greater compliance costs and disrupt product manufacturing and distribution. Failing to adapt to evolving customer preferences related to climate change could also lead to a loss of market share, adversely impacting Haemonetics’ financial stability and operational results.
Overall, Wall Street has a Strong Buy consensus rating on HAE stock based on 3 Buys and 1 Hold.
To learn more about Haemonetics’ risk factors, click here.